Comparative Pharmacology
Head-to-head clinical analysis: STILBETIN versus THEELIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STILBETIN versus THEELIN.
STILBETIN vs THEELIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diethylstilbestrol (STILBETIN) is a nonsteroidal estrogen that binds to estrogen receptors, activating estrogen-responsive genes, leading to increased synthesis of proteins involved in growth and differentiation of female reproductive tissues.
Estrogen receptor agonist; binds to estrogen receptors (ERα and ERβ), modulating gene transcription and promoting estrogenic effects.
25 mg orally 3 times daily for 5 days; repeat if necessary after 1 month.
Intramuscular: 0.22 to 1.1 mg (220 to 1100 mcg) once weekly for menopausal symptoms; 0.5 to 2 mg (500 to 2000 mcg) once weekly for prostatic carcinoma.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 hours (range 1-3 h) for estradiol; clinical relevance: requires multiple daily dosing (e.g., 3-4 times/day) for sustained effect.
Terminal elimination half-life: 13–19 hours (mean 16 h); clinical context: supports once-daily dosing for estrogen replacement.
Primarily renal as glucuronide and sulfate conjugates; approximately 50-80% of a parenteral dose excreted in urine within 24 hours; 10-20% via bile into feces.
Renal: ~50% as glucuronide and sulfate conjugates; fecal: ~30% via enterohepatic recirculation; biliary: ~20%.
Category C
Category C
Estrogen
Estrogen